![Julie DiCarlo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Julie DiCarlo
Plus aucun poste en cours
Profil
Julie DiCarlo worked as the Senior Director of Corporate Communications at Cubist Pharmaceuticals LLC.
She then served as the Head of Investor & Media Relations at Epizyme, Inc. Following that, she held the position of Senior VP of Investor Relations & Communications at PureTech Health Plc.
Lastly, she worked as the Senior Vice President and Head of Communications at Akili, Inc. Ms. DiCarlo completed her undergraduate degree at Towson University.
Anciens postes connus de Julie DiCarlo
Sociétés | Poste | Fin |
---|---|---|
AKILI, INC. | Public Communications Contact | - |
PURETECH HEALTH PLC | Investor Relations Contact | - |
EPIZYME, INC. | Investor Relations Contact | - |
CUBIST PHARMACEUTICALS INC | Public Communications Contact | - |
Formation de Julie DiCarlo
Towson University | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
Sociétés cotées | 2 |
---|---|
PURETECH HEALTH PLC | Health Technology |
AKILI, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Cubist Pharmaceuticals LLC
![]() Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Epizyme, Inc.
![]() Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |